ArticleDigital health
Strategic pathways of digital health platforms in regulated markets: Evidence from wearable devices.
Article in Digital health. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Wearable digital health platforms increasingly operate at the boundary between consumer wellness and regulated medical applications. While platform strategies such as openness toward complementors have been widely discussed, less is known about how digital health platforms strategically balance openness, closedness, and regulation over time in real-world healthcare settings. Objective: This study aims to examine how direct-to-consumer digital health platforms navigate regulatory environments and how strategic differences shape divergent innovation trajectories. Methods: We conducted a qualitative comparative case study of two leading wearable digital health platforms, Fitbit and Apple Watch. Using longitudinal secondary data on product launches, FDA-certified applications, clinical trial activities, and partnership histories, we analysed platform strategies at the levels of product development, market expansion, and business development. Results: The analysis reveals contrasting strategic pathways. Fitbit, as an early entrant, initially achieved market leadership through wellness oriented applications but became constrained by path-dependent strategies and limited regulatory engagement. In contrast, Apple leveraged regulatory reforms to introduce FDA-approved medical applications, combined openness toward third-party developers with closed control over core technologies, and actively engaged with regulators to create new growth paths. These differences resulted in divergent innovation trajectories despite operating in the same product category. Conclusions: This study demonstrates that regulation plays a central role in shaping digital health platform innovation, functioning not only as a constraint but also as an enabler when strategically integrated. By positioning regulation alongside openness and closedness as a core strategic dimension, the findings contribute to understanding how digital health platforms can sustain competitiveness in regulated environments and offer practical insights for managers and policymakers involved in digital health implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.